Fortis ties up with US co for stem cell research

Our Bureau New Delhi | Updated on March 14, 2011



Fortis Healthcare (India) Ltd has partnered with California-based TotipotentRX Cell Therapy Pvt Ltd to set up centres of excellence offering cellular therapies and stem cell clinical trials, across select Fortis hospitals. These centres will undertake stem cell clinical research procedures relating to diabetes, cancer, cardiovascular disease, and neurological ischemia. TotipotentRX will also set up laboratories in select hospitals, for processing stem cells before transplantation to patients.

TotipotentRX will leverage Fortis' hospital network and respective areas of clinical expertise to investigate new regenerative therapies, using promising adult stem cell sources such as cord blood, bone marrow, and adipose tissue. As part of the alliance, a Stem Cell Medical Board will be created to oversee the medical research programme, ensure execution and monitor the progress following international and Indian ethical guidelines. The board will also impart training and create awareness about benefits of stem cell therapy across India.

Mr Shivinder Mohan Singh, Managing Director, Fortis Healthcare, said, “This is in continuation of our effort to bring the latest in medicine to our customers, in a caring environment and at affordable prices.”

Stem Cell therapy is widely recognised to be the future of medicine due to its proven ability to repair and regenerate damaged and diseased organs and tissues.

Published on March 14, 2011

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like